AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7521313 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study 2653621 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 227
Study 117493 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 16
Study 117493 — intervention group
Group type: COMPARATOR
Intervention: Control and anxiety levels
Number of subjects: 16
Study 117493 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress levels
Number of subjects: 16
Study 31630035 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (CBX) adjunctive treatment
Number of subjects: 47
Study 31630035 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 47
Study 30885268 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study 30885268 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 27613646 — intervention group
Group type: EXPERIMENTAL
Intervention: Social self-value empowerment intervention (six weekly sessions)
Number of subjects: 132
Study 27613646 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 132
Study 26391131 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP >3 mg/L
Number of subjects: 10456
Study 26391131 — intervention group
Group type: COMPARATOR
Intervention: hsCRP <1 mg/L
Number of subjects: 10456
Study 24259978 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg AMT before bedtime
Number of subjects: 34
Study 24259978 — intervention group
Group type: COMPARATOR
Intervention: 40 mg Pantoprazole once daily for 4 weeks
Number of subjects: 34
Study 22309474 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week psychosocial treatment involving parent management training for ADHD and family-based cognitive-behavioral therapy for anxiety.
Number of subjects: 8
Study 22309474 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week psychosocial treatment
Number of subjects: 8
Study 22309474 — intervention group
Group type: COMPARATOR
Intervention: Baseline control conditions (2, 3, or 4 weeks)
Number of subjects: 8
Study 20195183 — intervention group
Group type: COMPARATOR
Intervention: Cycling (CYC; 60 min, 70% V˙O2peak)
Number of subjects: 16
Study 20195183 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance (REX; 8 x 5 leg extension, 80% one‐repetition maximum, 3‐min recovery)
Number of subjects: 16
Study 17646509 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 16 mg IV
Number of subjects: 100
Study 17646509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 16254089 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenegotiation affective trust
Number of subjects: 0
Study 16254089 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnegotiation cognitive trust
Number of subjects: 0
Study 16254089 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective trust
Number of subjects: 0
Study 16254089 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest turning points
Number of subjects: 0
Study 16254089 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative characterization turning points
Number of subjects: 0
Study 12190056 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based direct mail campaign
Number of subjects: 424
Study 12190056 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 424
Study 10442276 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 10442276 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (Control)
Number of subjects: 0
Study 7884951 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg of ibuprofen
Number of subjects: 84192
Study 7884951 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg of ibuprofen
Number of subjects: 84192
Study 7884951 — intervention group
Group type: COMPARATOR
Intervention: 12 mg/kg of acetaminophen
Number of subjects: 84192
Study 2403997 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral physostigmine
Number of subjects: 12
Study 2403997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6453432 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise Enamel Bond
Number of subjects: 64
Study 6453432 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise White Sealant
Number of subjects: 64
Study 6453432 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Bonding Agent
Number of subjects: 64
Study 6453432 — intervention group
Group type: EXPERIMENTAL
Intervention: Estilux Glaze
Number of subjects: 64
Study 6453432 — intervention group
Group type: EXPERIMENTAL
Intervention: Uvio Seal
Number of subjects: 64
Study 30559054 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleogel‐S10
Number of subjects: 61
Study 30559054 — intervention group
Group type: COMPARATOR
Intervention: Octenilin® wound gel
Number of subjects: 61
Study 28132813 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD (lysergic acid diethylamide)
Number of subjects: 0
Study 28132813 — intervention group
Group type: COMPARATOR
Intervention: Ketanserin (5-HT2AR antagonist)
Number of subjects: 0
Study 25181938 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy and progressive muscle relaxation training plus routine nursing care
Number of subjects: 170
Study 25181938 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 170
Study 23740894 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRT (3 cycles of carboplatin and 5‐fluorouracil plus conventional radiotherapy, 66 Gy in 6.5 weeks)
Number of subjects: 85
Study 23740894 — intervention group
Group type: COMPARATOR
Intervention: CCB (hybrid accelerated radiotherapy, 70 Gy in 6 weeks)
Number of subjects: 85
Study 23740894 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRT
Number of subjects: 85
Study 23740894 — intervention group
Group type: COMPARATOR
Intervention: CCB
Number of subjects: 85
Study 21384392 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser treatments on one side of the body three times per week for 2 weeks
Number of subjects: 5
Study 21384392 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss supplement (Curva™) in conjunction with low-level laser treatments
Number of subjects: 5
Study 21384392 — intervention group
Group type: COMPARATOR
Intervention: Physician blinded photo evaluation
Number of subjects: 5
Study 21384392 — intervention group
Group type: COMPARATOR
Intervention: Satisfaction questionnaires
Number of subjects: 5
Study 21384392 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound measurements
Number of subjects: 5
Study 19928389 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeping at 0 degrees to 45 degrees
Number of subjects: 25
Study 17013479 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (pre and postoperative)
Number of subjects: 200
Study 17013479 — intervention group
Group type: COMPARATOR
Intervention: No medications (control group)
Number of subjects: 200
Study 15464863 — intervention group
Group type: EXPERIMENTAL
Intervention: drugs + rTMS (1 Hz, 0.6 T, 100 stimuli per day for 7 days, repeated at least twice yearly for 3 years)
Number of subjects: 2
Study 15464863 — intervention group
Group type: COMPARATOR
Intervention: drugs only
Number of subjects: 2
Study 11417923 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine + Melatonin
Number of subjects: 35
Study 11417923 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine + Placebo
Number of subjects: 35
Study 9236640 — intervention group
Group type: COMPARATOR
Intervention: 0 mg rhRIx
Number of subjects: 96
Study 9236640 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg rhRIx
Number of subjects: 96
Study 9236640 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg rhRIx
Number of subjects: 96
Study 9236640 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg rhRIx
Number of subjects: 96
Study 9236640 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 96
Study 7963141 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein-based high-degree hydrolysate (CHy)
Number of subjects: 82
Study 7963141 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formula (SF)
Number of subjects: 82
Study 7963141 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey-based low-degree hydrolysate (WHy)
Number of subjects: 82
Study 7963141 — intervention group
Group type: EXPERIMENTAL
Intervention: All formula-fed infants
Number of subjects: 82
Study 2821217 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive methods of pain control training
Number of subjects: 0
Study 2821217 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo medication
Number of subjects: 0
Study 2821217 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study 2821217 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (opiate antagonist)
Number of subjects: 0
Study 2821217 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 0
Study 2821217 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive methods of pain control with naloxone
Number of subjects: 0
Study 29170936 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic developmental behavioral intervention with speech generating device
Number of subjects: 58
Study 29170936 — intervention group
Group type: COMPARATOR
Intervention: Naturalistic developmental behavioral intervention without speech generating device
Number of subjects: 58
Study 27346650 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training and nutritional intervention (PTN)
Number of subjects: 80
Study 27346650 — intervention group
Group type: COMPARATOR
Intervention: Social support intervention (SoSu)
Number of subjects: 80
Study 25052161 — intervention group
Group type: EXPERIMENTAL
Intervention: YXBCM01 granule (5.5 g twice daily)
Number of subjects: 600
Study 25052161 — intervention group
Group type: COMPARATOR
Intervention: Topical therapy (calcipotriol betamethasone for the first 4 weeks and calcipotriol ointment for the remaining 8 weeks)
Number of subjects: 600
Study 23450320 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifamily group treatment for TBI
Number of subjects: 14
Study 20638322 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal group rehabilitation
Number of subjects: 14
Study 20638322 — intervention group
Group type: COMPARATOR
Intervention: Usual care physiotherapy
Number of subjects: 14
Study 19418093 — intervention group
Group type: EXPERIMENTAL
Intervention: Diathermy incision (group A)
Number of subjects: 369
Study 19418093 — intervention group
Group type: COMPARATOR
Intervention: Scalpel incision (group B)
Number of subjects: 369
Study 16260436 — intervention group
Group type: EXPERIMENTAL
Intervention: Demonstration of infant reflexes, attention, motor skills, and sleep-wake states (Group 1, n = 28)
Number of subjects: 84
Study 16260436 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing educational materials (Group 2, n = 31)
Number of subjects: 84
Study 16260436 — intervention group
Group type: COMPARATOR
Intervention: Informal discussion (Control Group 3, n = 25)
Number of subjects: 84
Study 12100060 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone 30 mg/day
Number of subjects: 120
Study 12100060 — intervention group
Group type: EXPERIMENTAL
Intervention: fluticasone propionate 1000 microg/day b.i.d.
Number of subjects: 120
Study 12100060 — intervention group
Group type: EXPERIMENTAL
Intervention: fluticasone propionate 250 microg/day b.i.d.
Number of subjects: 120
Study 12100060 — intervention group
Group type: EXPERIMENTAL
Intervention: High sputum eosinophils (> or = 3%)
Number of subjects: 120
Study 12100060 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophils in blood or sputum
Number of subjects: 120
Study 12100060 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 120
Study 10067139 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-focused task
Number of subjects: 70
Study 10067139 — intervention group
Group type: COMPARATOR
Intervention: Distracting task
Number of subjects: 70
Study 7717714 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) 600 mg/m2 plus high‐dose l‐leucovorin (l‐LV) 250 mg/m2, given weekly by i.v. injection
Number of subjects: 122
Study 7717714 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) 370 mg/m2 plus high‐dose l‐leucovorin (l‐LV) 100 mg/m2, given simultaneously for 5 consecutive days
Number of subjects: 122
Study 7717714 — intervention group
Group type: COMPARATOR
Intervention: 5‐fluorouracil (5‐FU) 370 mg/m2 plus low‐dose l‐leucovorin (l‐LV) 10 mg/m2, given with the same schedule as regimen B
Number of subjects: 122
Study 1790311 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentacard 20 mg tablets
Number of subjects: 12
Study 1790311 — intervention group
Group type: COMPARATOR
Intervention: Ismo 20 mg tablets
Number of subjects: 12
Study 7248480 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination (Inderetic) of 80 mg propranolol twice daily and 2.5 mg bendrofluazide twice daily
Number of subjects: 12
Study 7248480 — intervention group
Group type: COMPARATOR
Intervention: Free combination of 80 mg propranolol twice daily and 2.5 mg bendrofluazide twice daily
Number of subjects: 12
Study 30826050 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel loading dose (LD)
Number of subjects: 802
Study 30826050 — intervention group
Group type: COMPARATOR
Intervention: No loading dose (NLD)
Number of subjects: 802
Study 30826050 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel maintenance therapy
Number of subjects: 802
Study 30826050 — intervention group
Group type: COMPARATOR
Intervention: No clopidogrel maintenance therapy
Number of subjects: 802
Study 28827938 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey (20 mL)
Number of subjects: 82
Study 28827938 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 82
Study 25399224 — intervention group
Group type: EXPERIMENTAL
Intervention: Site-specific disinfection method using Listerine Cool Mint mouth rinse
Number of subjects: 20
Study 25399224 — intervention group
Group type: COMPARATOR
Intervention: Traditional panoral rinsing method using Listerine Cool Mint mouth rinse
Number of subjects: 20
Study 23061313 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Motivational Interviewing plus Brief Cognitive Behavior Therapy (GMI‐BCBT) plus usual care
Number of subjects: 200
Study 23061313 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 19238802 — intervention group
Group type: EXPERIMENTAL
Intervention: XP13512 1800 mg/day
Number of subjects: 38
Study 16380286 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar spine mobilization, exercise, and slump stretching
Number of subjects: 30
Study 16380286 — intervention group
Group type: COMPARATOR
Intervention: Lumbar spine mobilization and exercise
Number of subjects: 30
Study 12514593 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed saphenous venous bypass
Number of subjects: 151
Study 12514593 — intervention group
Group type: COMPARATOR
Intervention: Polytetrafluoroethylene bypass
Number of subjects: 151
Study 10791216 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannite solution (10%); 2000 mL during the first 2 hours, then 2000 mL per day until no rectal blood observed.
Number of subjects: 39
Study 10791216 — intervention group
Group type: COMPARATOR
Intervention: Paromomycine (1 g tid) and lactulose (10 mL tid)
Number of subjects: 39
Study 10791216 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannite solution (10%)
Number of subjects: 39
Study 10791216 — intervention group
Group type: COMPARATOR
Intervention: Paromomycine and lactulose
Number of subjects: 39
Study 8876703 — intervention group
Group type: EXPERIMENTAL
Intervention: Atamestane 100 mg
Number of subjects: 292
Study 8876703 — intervention group
Group type: EXPERIMENTAL
Intervention: Atamestane 300 mg
Number of subjects: 292
Study 8876703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 1496141 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (20 Gy in 10 treatments over 2 weeks)
Number of subjects: 176
Study 1496141 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 176
Study 6088309 — intervention group
Group type: EXPERIMENTAL
Intervention: Solcoderm
Number of subjects: 0
Study 6088309 — intervention group
Group type: COMPARATOR
Intervention: Plain nitric acid
Number of subjects: 0
Study 6088309 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of oxalic and nitric acid
Number of subjects: 0
Study 6088309 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetic and nitric acid
Number of subjects: 0
Study 31633643 — intervention group
Group type: EXPERIMENTAL
Intervention: TightRope (1 knotless TightRope)
Number of subjects: 103
Study 31633643 — intervention group
Group type: COMPARATOR
Intervention: Screw fixation (two 3.5‐mm cortical positional screws)
Number of subjects: 103
Study 31633643 — intervention group
Group type: EXPERIMENTAL
Intervention: TightRope
Number of subjects: 103
Study 31633643 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional outcomes (Foot and Ankle Disability Index)
Number of subjects: 103
Study 31633643 — intervention group
Group type: COMPARATOR
Intervention: Screw fixation
Number of subjects: 103
Study 29168044 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy (SRT, IRay)
Number of subjects: 468
Study 29168044 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 468
Study 26717873 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-initiated daily verbal reminders
Number of subjects: 0
Study 26717873 — intervention group
Group type: COMPARATOR
Intervention: Nurse-initiated daily verbal reminders
Number of subjects: 0
Study 24727333 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05%
Number of subjects: 32
Study 24727333 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 0.1 mg/mL
Number of subjects: 32
Study 22113369 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training (n = 24)
Number of subjects: 50
Study 22113369 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 26)
Number of subjects: 50
Study 21054769 — intervention group
Group type: EXPERIMENTAL
Intervention: 320/25 mg valsartan/hydrochlorothiazide (HCTZ)
Number of subjects: 421
Study 21054769 — intervention group
Group type: COMPARATOR
Intervention: 10/25 mg amlodipine/HCTZ
Number of subjects: 421
Study 17425487 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmoteplase
Number of subjects: 0
Study 17425487 — intervention group
Group type: COMPARATOR
Intervention: Control (currently approved treatment options)
Number of subjects: 0
Study 16235865 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided health imagery intervention group
Number of subjects: 71
Study 16235865 — intervention group
Group type: COMPARATOR
Intervention: Placebo-control group
Number of subjects: 71
Study 12202606 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipstick assay for Brucella-specific immunoglobulin M
Number of subjects: 85
Study 12202606 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipstick assay for typhoid-specific immunoglobulin M
Number of subjects: 85
Study 10540089 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil with propofol (target plasma concentration of remifentanil varied while maintaining propofol at 4.5 microg x ml-1)
Number of subjects: 20
Study 10540089 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (target concentrations)
Number of subjects: 20
Study 8529777 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg d-alpha-tocopheryl acetate daily
Number of subjects: 161
Study 8529777 — intervention group
Group type: COMPARATOR
Intervention: 3 mg d-alpha-tocopheryl acetate daily
Number of subjects: 161
Study 2160172 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential combined with hemoperfusion
Number of subjects: 64
Study 2160172 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with hemoperfusion
Number of subjects: 64
Study 2160172 — intervention group
Group type: EXPERIMENTAL
Intervention: Teturam
Number of subjects: 64
Study 467093 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 5-fluorocytosine (1000 mg) and candicidin (5 mg)
Number of subjects: 112
Study 467093 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole (100 mg)
Number of subjects: 112
Study 31082898 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (500 μg bolus followed by 250 μg/h infusion for 5 days)
Number of subjects: 33
Study 31082898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 28734043 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg/d)
Number of subjects: 300
Study 28734043 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fish oil (2.8 g/d)
Number of subjects: 300
Study 28734043 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined losartan and omega-3 fish oil
Number of subjects: 300
Study 28734043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 25952309 — intervention group
Group type: EXPERIMENTAL
Intervention: White-Light (WL) colonoscopy
Number of subjects: 159
Study 25952309 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-Band Imaging (NBI) colonoscopy
Number of subjects: 159
Study 22753310 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen ablation (AA)
Number of subjects: 79
Study 22753310 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen ablation (AA) with chemotherapy
Number of subjects: 79
Study 22753310 — intervention group
Group type: COMPARATOR
Intervention: Control group (stage- and grade-matched)
Number of subjects: 79
Study 21730792 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nylon dressing
Number of subjects: 110
Study 21730792 — intervention group
Group type: COMPARATOR
Intervention: Gauze dressing
Number of subjects: 110
Study 21730792 — intervention group
Group type: COMPARATOR
Intervention: Control group (Gauze dressing)
Number of subjects: 110
Study 19701112 — intervention group
Group type: EXPERIMENTAL
Intervention: Iyengar yoga therapy
Number of subjects: 90
Study 19701112 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 90
Study 16954134 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (atorvastatin 80 mg)
Number of subjects: 978
Study 16954134 — intervention group
Group type: COMPARATOR
Intervention: Standard statin therapy (pravastatin 40 mg)
Number of subjects: 978